Home/Pipeline/REC-3565

REC-3565

B-cell Malignancies

Phase 1Active

Key Facts

Indication

B-cell Malignancies

Phase

Phase 1

Status

Active

Company

Recursion Pharmaceuticals

About Recursion Pharmaceuticals

Recursion Pharmaceuticals is pioneering a TechBio approach to industrialize drug discovery, leveraging its proprietary Recursion OS—a closed-loop platform integrating automated wet labs, one of the world's largest fit-for-purpose biological datasets (>50 PB), and machine learning foundation models. The company has built a maturing clinical pipeline, with its lead asset, REC-4881 for Familial Adenomatous Polyposis (FAP), in Phase 2 and multiple other oncology programs in Phase 1/2. Its strategy centers on scaling its platform to systematically discover and develop first-in-class and best-in-class medicines, supported by strategic partnerships with pharmaceutical and technology leaders.

View full company profile

Therapeutic Areas

Oncology Rare Disease

Other B-cell Malignancies Drugs

Drug	Company	Phase	Status
CAR-T Program (Hematological)	XellSmart	Phase 1	Active
BAFFR Allo CAR-NK Cells	PeproMene Bio	Pre-clinical	Active
IKS03	Iksuda Therapeutics	Clinical	Active
TNB-486	Ancora Bio	Phase 1	Active
docirbrutinib (AS-1763)	Carna Biosciences	Phase 1b	Active
Abivertinib	Sorrento Therapeutics	Phase 1/2	Active
Kymriah® (tisagenlecleucel)	Novartis	Approved	Active
KITE-363	Gilead Sciences	Phase 1/2	Active
HSK29116	Haisco Pharmaceutical Group	Phase I/II	Active
TG-1701	TG Therapeutics	Phase 1	Active
TG-1801	TG Therapeutics	Phase 1	Active
Plamotamab (XmAb®13676)	Xencor	Phase 2	Active (Partnered)